The ongoing phase I trial of CCR4 CAR T cells for PTCL and CTCL (NCT07055477) should provide further insights into the safety profile of this agent. This evidence concerns the gene CCR4 and mature T-cell and NK-cell non-Hodgkin lymphoma.